Ultragenyx Pharmaceutical (NASDAQ:RARE) Announces Quarterly Earnings Results

Ultragenyx Pharmaceutical (NASDAQ:RARE) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.01), Bloomberg Earnings reports. The company had revenue of $35.59 million for the quarter, compared to the consensus estimate of $32.31 million. Ultragenyx Pharmaceutical had a negative return on equity of 52.16% and a negative net margin of 470.18%.

Shares of RARE traded down $1.71 during mid-day trading on Friday, hitting $61.19. The company’s stock had a trading volume of 37,752 shares, compared to its average volume of 586,843. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.79 and a quick ratio of 6.64. The firm has a 50-day moving average price of $53.58 and a 200 day moving average price of $47.87. Ultragenyx Pharmaceutical has a fifty-two week low of $35.41 and a fifty-two week high of $74.50. The stock has a market capitalization of $3.63 billion, a price-to-earnings ratio of -8.46 and a beta of 2.35.

In related news, SVP Theodore Alan Huizenga sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $61.00, for a total transaction of $61,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.80% of the stock is owned by insiders.

Several research firms have recently issued reports on RARE. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Tuesday. Morgan Stanley boosted their target price on Ultragenyx Pharmaceutical from $73.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Wedbush upped their target price on Ultragenyx Pharmaceutical from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Friday. Raymond James lowered Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 2nd. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $70.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, December 18th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $74.83.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Further Reading: What is a stock buyback?

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.